F-star bags third Takeda tie-up in a year with multi-specific antibodies for cancer

The stars have aligned for the third time between invoX Pharma’s F-star and Takeda as the duo gets to work on another antibody pact, with an aim to create new immunotherapies for undisclosed cancers.

The new partnership centers around multi-specific antibodies using F-star’s so-called Fcab and tetravalent monoclonal antibody platforms, and it follows deals around bispecific antibodies that the companies made in July 2022 and in March.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

Isospec Analytics Secures $1.9M to Transform Molecular Identification

What You Should Know: – When developing new drugs, nutritional products, or pesticides, it’s critical that unknown molecules are identified correctly. But accurate identification is

April 17, 2024

Clinical Challenges: Discussing Childhood Vaccination With Hesitant Parents

“Nearly all pediatricians encounter parents who want to do what is best for their child — even though it may mean they have questions about

November 4, 2023

Dark chocolate cuts hypertension risk: Sweet news from latest study

Study finds dark chocolate intake significantly lowers the risk of essential hypertension, suggesting a beneficial role in cardiovascular health.

January 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.